Zanubrutinib Oral Product Clinical Trials
2 recruitingDrug
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy
Monoclonal Gammopathy of Uncertain Significance
UMC Utrecht35 enrolled1 locationNCT05939037
Recruiting
Phase 2
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
PETHEMA Foundation106 enrolled1 locationNCT06544785